Cue Biopharma, Inc.
CUE evidence brief
What we can confirm
- BioSniper Score:
- 4.1 / 10
- Market Cap:
- $185.3M
- Lead Asset:
- CUE-101 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CUE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing therapeutic biologics to selectively engage and modulate disease-specific T cells, with lead assets CUE-221 and CUE-401 in autoimmune/inflammatory disease and food allergy applications.
Key risk: Cash runway
BioSniper Score
Based on 4 of 6 signals
Market Cap
$185.3M
Cash Runway
—
Lead Asset
CUE-101 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 4 clinical trials for Cue Biopharma, Inc..
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing therapeutic biologics to selectively engage and modulate disease-specific T cells, with lead assets CUE-221 and CUE-401 in autoimmune/inflammatory disease and food allergy applications.
- Cash & equivalents of $17.4M as of 2026-06-30 [sec]
- Total revenue of $7.9M and net loss of -$153.1M as of 2026-06-30 [sec]
- Completed a $50 million private placement (PIPE) in Q2 2026 [news · 2026-08-14]
- Lead assets CUE-221 (food allergy) and CUE-401 (autoimmune/inflammatory) are the focus of development [sec_mda · as of 2026-08-14]
- Deprioritized CUE-100 series (CUE-101, CUE-102) licensed to IMSCP for oncology [sec_mda · as of 2026-08-14]
What works
- Completed a $50M private placement to fund clinical development and portfolio expansion [news · 2026-08-14]
- CUE-101 combination with KEYTRUDA showed 12-month OS of 88% vs 57% historical (KEYNOTE-048) and median OS of 32.7 months vs 12.3 months [sec_mda · as of 2025-11-12]
- Strategic collaborations with BI (CUE-501) and ImmunoScape (CUE-100 series) provide non-dilutive funding and development support [sec_mda · as of 2026-08-14]
What to weigh
- Company has incurred significant losses since inception and never generated revenue or profit from product sales [sec_mda · as of 2026-08-14]
- Net loss of -$153.1M and shareholders' equity of only $2.3M as of 2026-06-30 [sec]
- Cash runway limited to $17.4M as of 2026-06-30, with ongoing R&D and clinical trial expenses expected to increase [sec]
- CUE-100 series (CUE-101, CUE-102) deprioritized and licensed out, reducing internal pipeline breadth [sec_mda · as of 2026-08-14]
From the filings
Quoted directly from source documents.
Company has never generated revenue from product sales
“We have incurred significant losses since our inception and have never generated revenue or profit from product sales”
SEC MD&A · August 14, 2026
CUE-101 combination showed improved OS vs historical control
“12-month overall survival (OS) of 88% compared to 57% with KEYTRUDA alone in the historical KEYNOTE-048 trial, representing an unprecedented reduction in the risk of death (hazard ratio of 0.23) compared to historical data.”
SEC MD&A · November 12, 2025
Completed $50M private placement in Q2 2026
“Completed a $50 million private placement (PIPE) to further fund clinical development and the portfolio with significant potential for value-inflection”
News · August 14, 2026
Lead assets are CUE-221 and CUE-401
“We intend that the majority of our business activities will be devoted to furthering the development of our two lead assets: CUE-221 and CUE-401.”
SEC MD&A · August 14, 2026
Catalyst timeline
- 2019-07-30 · Phase 1 start of CUE-101 monotherapy/combination with pembrolizumab in HPV16+ HNSCC — First-in-human study for CUE-101, now deprioritized and licensed to IMSCP.
- 2022-06-14 · Phase 1 start of CUE-102 monotherapy in WT1-positive cancers — CUE-102 study initiated; asset later deprioritized and licensed to IMSCP.
- 2026-02-01 · Phase 2 start of Givastomig (TJ033721) combination study in CLDN18.2/PD-L1 positive gastric cancer — This is a separate collaboration asset; not a Cue Biopharma internal program.
Risks & what to watch (3)›
Key risks
- Cash runway — Cash & equivalents of $17.4M as of 2026-06-30, with ongoing R&D expenses and no product revenue [sec]
- No product revenue — Company has never generated revenue or profit from product sales, relying on financing and collaborations [sec_mda · as of 2026-08-14]
- Clinical-stage uncertainty — Lead assets CUE-221 and CUE-401 are in early development; CUE-221 IND submitted, CUE-401 preclinical [news · 2026-08-14]
What to watch
- CUE-221 IND submission for food allergy applications and subsequent clinical trial initiation [news · 2026-08-14]
- CUE-401 IND readiness and potential clinical start for autoimmune/inflammatory diseases [news · 2026-03-16]
- Cash burn rate and need for additional financing given $17.4M cash position and $153.1M net loss [sec]
- Progress of collaborations with BI (CUE-501) and ImmunoScape (CUE-100 series) for potential milestones [sec_mda · as of 2026-08-14]
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 14, 2026 · How we verify sources →
Run Cue Biopharma, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cue Biopharma, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 12.29 · 0% dilution
Lead: Phase 1
4 candidates
No upcoming catalysts tracked
2 buys · 11 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
56
Total value held
$4.9M
| Holder | Shares | Value |
|---|---|---|
| bleichroeder lp | 6,819,164 | $1.6M |
| gc wealth management ria, llc | 4,631,644 | $1.1M |
| vanguard capital management llc | 2,457,452 | $565K |
| lion point capital, lp | 2,202,854 | $506K |
| geode capital management, llc | 1,064,690 | $245K |
| vanguard fiduciary trust co | 543,585 | $125K |
| robertson stephens wealth management, llc | 478,500 | $110K |
| blackrock, inc. | 449,161 | $103K |
| texas capital bank wealth management services inc | 397,421 | $91K |
| angeles wealth management, llc | 310,000 | $71K |
Showing top 10 of 56 institutional holders of Cue Biopharma, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 8.9%
- Days to cover
- 0.3
- Shares short
- 288,887
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CUE short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cue Biopharma, Inc.?
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing therapeutic biologics to selectively engage and modulate disease-specific T cells, with lead assets CUE-221 and CUE-401 in autoimmune/inflammatory disease and food allergy applications.
What is Cue Biopharma, Inc.'s lead drug candidate?
Cue Biopharma, Inc.'s most advanced tracked candidate is CUE-101 (Phase 1) for Head and Neck Cancer.
Who is the CEO of Cue Biopharma, Inc.?
Dr. Shao-Lee Lin M.D., Ph.D. is the chief executive officer of Cue Biopharma, Inc. (CUE).
Where is Cue Biopharma, Inc. headquartered?
Cue Biopharma, Inc. (CUE) is headquartered in Boston, MA, United States.
What therapeutic areas does Cue Biopharma, Inc. focus on?
Cue Biopharma, Inc. develops therapies across Oncology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.